Test for Sensitive Detection and Accurate Assignment of TP53 Variants in Tumor DNA

摘要

Accurate, sensitive assessment of the mutational status of tumors enables genotype/phenotype studies and increases the understanding of tumor etiology, progression, recurrence and response to therapy. Preliminary Peptide Mass Signature Genotyping (PMSG) results using bacterial cultures indicated tremendous potential and proof of concept experiments demonstrated that the PMSG process could be converted to an in vitro test. Expansion of proof of concept protocols will provide a mutation detection process suitable for validation and clinical testing.